The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis by Mair-Jenkins, John et al.
R E V I E W
The Effectiveness of Convalescent Plasma and
Hyperimmune Immunoglobulin for the
Treatment of Severe Acute Respiratory Infections
of Viral Etiology: A Systematic Review and
Exploratory Meta-analysis
John Mair-Jenkins,1,a Maria Saavedra-Campos,4,5,a J. Kenneth Baillie,6 Paul Cleary,5 Fu-Meng Khaw,1 Wei Shen Lim,2
Sophia Makki,1 Kevin D. Rooney,7 Convalescent Plasma Study Group,b Jonathan S. Nguyen-Van-Tam,3 and
Charles R. Beck3
1East Midlands Centre, Public Health England, 2Respiratory Medicine, Nottingham University Hospitals NHS Trust, and 3Division of Epidemiology and
Public Health, University of Nottingham, Nottingham; 4Field Epidemiology Training Programme, Public Health England, London; 5Field Epidemiology
Service, Public Health England, Liverpool; 6Roslin Institute, University of Edinburgh, Midlothian; and 7Institute of Care and Practice Improvement, University
of the West of Scotland, Hamilton, United Kingdom
Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clin-
ical beneﬁt for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic
review and exploratory meta-analysis to assess the overall evidence.
Methods. Healthcare databases and sources of grey literature were searched in July 2013. All records were
screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments
were undertaken.
Results. We identiﬁed 32 studies of SARS coronavirus infection and severe inﬂuenza. Narrative analyses revealed
consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after
symptom onset. Exploratory post hoc meta-analysis showed a statistically signiﬁcant reduction in the pooled
odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% conﬁdence
interval, .14–.45; I2 = 0%). Studies were commonly of low or very low quality, lacked control groups, and at moderate
or high risk of bias. Sources of clinical and methodological heterogeneity were identiﬁed.
Conclusions. Convalescent plasma may reduce mortality and appears safe. This therapy should be studied with-
in the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East
respiratory syndrome coronavirus CoV infection.
Keywords. MERS coronavirus; convalescent plasma; severe acute respiratory infection; systematic review;
meta-analysis.
As of 23 May 2014, the World Health Organization
(WHO) had been informed of 635 persons with labora-
tory-conﬁrmed Middle East respiratory syndrome coro-
navirus (MERS-CoV) infection, of whom 193 (30%)
have died [1]. The current approach to clinical manage-
ment of MERS-CoV infection centers on general sup-
portive care, with provision of critical care and organ
support when necessary [2]. It has recently been sug-
gested that administration of convalescent plasma or
hyperimmune immunoglobulin will yield a clinical ef-
fect for treatment of MERS-CoV infection [3].However,
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numerous uncertainties remain because the clinical course, viral
replication kinetics, and host interactions are yet to be fully es-
tablished [4]. Furthermore, the underlying evidence is based on
studies of varying size and quality that describe clinical experi-
ence in treating other viral infections, including those due to
SARS coronavirus (SARS-CoV), Spanish inﬂuenza A(H1N1),
avian inﬂuenza A(H5N1), and 2009 pandemic inﬂuenza A
(H1N1) (hereafter, “inﬂuenza A[H1N1]pdm09”) [5–9].
We conducted a systematic review and exploratory meta-anal-
ysis to evaluate the clinical effectiveness of convalescent plasma,
serum, or hyperimmune immunoglobulin for the treatment of
severe acute respiratory infections (SARIs) of viral etiology, to
help inform clinical management of MERS-CoV infection.
METHODS
This systematic review was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [10]. The study protocol was
registered with the National Institute for Health Research inter-
national prospective register of systematic reviews [11].
The study eligibility criteria are available elsewhere [11].
Brieﬂy, the study population of interest was human subjects
of any age or sex who were hospitalized with SARIs with a
laboratory-conﬁrmed or suspected viral etiology. The interven-
tion of interest was convalescent plasma, serum, or hyperim-
mune immunoglobulin derived from convalescent plasma.
Comparator treatments included placebo, sham therapy, or no
intervention; studies with no comparator group were also includ-
ed. Outcome measures were derived from the protocol research
questions to ascertain the clinical effectiveness of therapy [11].
Search Strategy and Study Selection
Two reviewers (J. M.-J. and M. S.-C.) executed the search strategy
in July 2013. The sources of information searched and search con-
struct are available elsewhere [11]. Adaptations were made for
search interfaces that did not allow use of complex constructs.
All search records were imported to EndNote X5 software (Thom-
son Reuters, San Francisco, CA) or screenedmanually, using paper
records. Following the removal of duplicate entries, a 3-stage
screening process was followed to identify eligible records through
the sequential examination of each title, abstract, and full text. Two
reviewers (J. M.-J. and M. S.-C.) screened each record, with provi-
sion for arbitration from a third reviewer (C. R. B.).
Data Collection
Data were collected independently by paired reviewers, using a
piloted form. Consensus agreement for each extracted data item
was reached by discussion, with provision for arbitration from a
third reviewer (J. M.-J., M. S.-C., and C. R. B.). The data extrac-
tion form is available as an appendix to the study protocol [11].
Risk of Bias Within Studies
Risk of bias assessments were performed at the outcome mea-
sure level during data collection. The Cochrane Collaboration
tool was used for experimental and prospective cohort studies
[12], the Newcastle-Ottawa scale was used for observational
studies (excluding prospective cohort studies) [13], and a tool
published by the US Agency for Healthcare Research and Qual-
ity was used for systematic reviews [14]. Records limited to ab-
stracts were not assessed, because of the paucity of information
contained therein.
Summary Measures and Synthesis of Results
Odds ratios (ORs), case-fatality rates (CFRs), absolute differenc-
es in CFRs, and difference in means were calculated as summary
statistics with 95% conﬁdence intervals (CIs). Study character-
istics and outcome measures were tabulated. A recognized
framework for narrative synthesis was adopted [15]. Because
of potential concerns with clinical heterogeneity, analyses
were stratiﬁed by viral etiology for each research question in
accordance with the protocol [11].
An exploratory, post hoc, random-effects-model meta-
analysis was conducted to describe the pooled OR of mortality,
irrespective of SARI etiology, following treatment with conva-
lescent plasma or serum, using the odds after receipt of placebo
or no therapy as a reference. Results were adjusted by adding 0.5
to each cell of the contingency table when no deaths occurred in
the exposed group in individual studies [12]. Meta-analysis of
crude CFRs, using a random-effects model, was undertaken.
Statistical heterogeneity was ascertained using the I2 statistic,
and meta-analyses were abandoned when this reached 85%
[16]. Sensitivity analyses were undertaken to investigate the im-
pact of excluding studies with ≤5 patients in the exposed group.
Publication bias was assessed through construction of funnel
plots and by use of the Egger test.
All statistical analyses were conducted using Stata soft-
ware, version 12.1 (StataCorp, College Station, TX), except
for meta-analysis of pooled proportions, for which we used
StatsDirect software, version 2.8.0 (StatsDirect, Altrincham,
United Kingdom). Statistical signiﬁcance was assumed at
the 5% level.
RESULTS
Study Selection
The search process yielded 3406 records (Figure 1). After sifting
1449 unique records against the protocol eligibility criteria, we
identiﬁed 32 studies from 50 reports (Supplementary Table 1).
Three studies could not be obtained [17–19], although results
from a study by Bass et al [17] were reported elsewhere [20],
which enabled their inclusion. French (n = 1), German
(n = 2), and Korean (n = 2) records were screened by single re-
viewers because of a lack of multilingual collaborators.
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Study Characteristics
The study characteristics are summarized in Supplementary
Table 2. Three systematic reviews met our protocol eligibility
criteria [7, 21, 22]. Data on 1327 patients from 6 case studies
[23–28], 20 case series [8, 17, 20, 29–45], 2 case-comparison
studies [46, 47], and 1 prospective cohort [48] were included.
We identiﬁed 13 observational studies published between
1918 and 1920, which studied 980 patients who received a clin-
ical diagnosis of inﬂuenza-associated pneumonia or Spanish
inﬂuenza A (H1N1) infection [17, 20, 33–35, 38–44, 47]. It is un-
clear whether some of these studies recruited patients with sec-
ondary bacterial pneumonia. Sixteen observational studies that
met our protocol eligibility criteria were published between
2003 and 2011. Four studies reported outcomes for 29 patients
infected with avian inﬂuenza A(H5N1) [23, 26, 27, 36], 4 studies
reported outcomes for 104 patients infected with inﬂuenza A
(H1N1)pdm09 [24, 30, 37, 48], and 8 studies reported outcomes
for 214 patients with SARS [8, 25, 28, 29, 31, 32, 45, 46]. The
clinical status of patients at the time of treatment administration
varied, as did concomitant treatments and comorbidities. Con-
valescent plasma was used in all observational studies of
SARS-CoV, inﬂuenza A(H1N1)pdm09, and avian inﬂuenza
A(H5N1) infections (Supplementary Table 2). For Spanish
inﬂuenza A(H1N1) infection, 2 observational studies used
convalescent plasma, and 11 used convalescent serum (Supple-
mentary Table 2). No studies that used hyperimmune immuno-
globulin met our protocol eligibility criteria. The use of sham
treatments or placebos was not reported.
Risk of Bias Within Studies
Two systematic reviews were at low risk of bias [7, 21], whereas
one was at moderate to low risk of bias across most domains
(Table 1) [22]. Data extraction was judged to be a moderate
source of bias in all systematic reviews. Search strategies were
also a moderate source of bias in 2 systematic reviews, as grey
literature and non–peer-reviewed sources were not considered
[7, 22].
The risks of bias of 2 outcomes in a single prospective cohort
study were considered to be moderate (Table 2) [48]. The lack of
randomized treatment allocation may have introduced system-
atic error, and the viral load outcome was at high risk of bias
because of incomplete follow-up of patients.
Figure 2 summarizes the risk of bias assessments for 44 out-
comes from 25 observational studies. Studies reported outcomes
that were either at moderate risk (11 outcomes) or moderate to
high risk of selection bias (33 outcomes). The majority of studies
lacked a comparator group, and 28 studies were at high or very
high risk of reporting bias. This suggests that the observational
study data included are at moderate to high risk of bias.
Three studies were not assessed for risk of bias, because they
presented insufﬁcient data [17, 29, 45].
Results of Individual Studies and Data Synthesis
Table 3 summarizes our narrative synthesis, and Supplementary
Table 3 shows results of the individual studies that included an
all-cause mortality outcome. Meta-analyses, sensitivity analyses,
and assessments of publication bias, by viral etiology, proved
unfeasible due to a paucity of suitable data. There were no
data available to address study questions relating to organ fail-
ure and sepsis or to hospital readmission and recurrence of
severe disease.
Mortality
SARS-CoV Infection
Table 3 and Supplementary 3 summarize 8 observational stud-
ies at moderate to high risk of bias that reported improved mor-
tality after patients received various doses of convalescent
plasma [8, 25, 28, 29, 31, 32, 45, 46]. A retrospective case-com-
parison study showed a CFR reduction after plasma treatment
that reached statistical signiﬁcance (absolute reduction in CFR,
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-
Analyses diagram. aRecords were rejected for the following reasons: not
population of interest, 12 records (1 in French, 1 in German, 1 in Italian, and
1 in Korean); no intervention of interest, 15 (1 in German); not suitable
comparator, 1; nonhuman study, 1; and no outcome of interest, 7.
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23%; 95% CI, 6%–42%; P = .049) [46]. A second study with a
comparator group described a cluster of 29 cases of SARS-
CoV infection in which 1 patient received convalescent plasma
and survived (absolute reduction in CFR, 7%; 95% CI, −2% to
17%; P = .93) [32, 49]. Three small studies reported treatment of
5 patients with no deaths, and a case series by Cheng et al re-
ported a CFR of 12.5% (10 of 80 patients) following treatment
(Supplementary Table 3) [8, 9, 25, 28, 31, 45, 50]. Within this se-
ries, a subgroup analysis of 30 patients found that those treated
when PCR-positive but seronegative for SARS-CoV were more
likely to be discharged within 22 days of admission than those
who were seropositive at the time of plasma infusion (67% vs
20%; P = .001). A further subgroup analysis of 48 patients
found that receipt of convalescent plasma treatment <14 days
after onset of symptoms improved the likelihood of discharge
within 22 days of admission (58% vs 16%; P < .001); this re-
mained signiﬁcant after adjustment for age, viral status, time
of administration, and lactate dehydrogenase level, suggesting
that early treatment with convalescent plasma may be beneﬁ-
cial. However, allocation of treatment was mostly based on
the physician’s decision and the availability of plasma, and
this study was at high risk of bias.
Inﬂuenza A(H1N1)pdm09 Infection
Four observational studies [24, 30, 37, 48] and 1 systematic review
[22] reported data on severe cases of inﬂuenza A(H1N1)pdm09
infection treated with convalescent plasma (Table 3 and Supple-
mentary Table 3). Hung et al [48] performed a prospective
cohort study in which patients received a single 500-mL dose
of convalescent plasma with a neutralizing antibody titer of
>1:160. Univariate analysis showed a signiﬁcant absolute reduc-
tion in CFR of 35% (95% CI, 14%–56%; P = .01) after treatment.
Multivariable analysis also showed a signiﬁcant reduction in the
relative risk of mortality (OR, 0.20; 95% CI, .06–.69; P = .011),
although the factors adjusted for were not clearly stated. Both
groups received other treatments, such as neuraminidase inhib-
itors and steroids (Supplementary Table 2). This nonrandomized
study was at moderate risk of bias. A small study by Chan et al
[30] at moderate risk of bias reported exclusively on patients who
received extracorporeal membrane oxygenation (ECMO) and
showed a nonsigniﬁcant absolute reduction of 33% (95% CI,
−20% to 87%) in the CFR after convalescent plasma treatment.
Avian Inﬂuenza A(H5N1) Infection
In a case series at high risk of bias, in which 2 of 26 patients re-
ceiving convalescent plasma, a nonsigniﬁcant absolute reduc-
tion of 70% (95% CI, 52%–89%; P = .11) in the CFR was
observed (Supplementary Table 3) [36]. Three case reports re-
ported recovery among patients who were treated with convales-
cent plasma [23, 26, 27]. The dose of convalescent plasma varied
across each study, and the neutralizing antibody titer was re-
ported for only 1 case (1:80) [26]. All studies were at high to
moderate risk of bias and had patients who were given other
therapies concomitantly (including steroids and antivirals),
which could have inﬂuenced the reported clinical effect.
Table 2. Risk of Bias Assessment in the Eligible Prospective
Cohort Study Using The Cochrane Collaboration Tool
Domain
Hung et al [48]:
Mortality
Hung et al [48]:
Viral Load
Sequence generation High risk of
bias
High risk of bias
Allocation concealment High risk of
bias
High risk of bias
Blinding of participants,
personnel, and outcome
assessors
High risk of
bias
Unclear risk of
bias
Incomplete outcome data Low risk of bias High risk of bias
Selective outcome reporting Low risk of bias Low risk of bias
Table 1. Risk of Bias Assessment in the Eligible Systematic Reviews Using US Agency for Healthcare Research and Quality Tool
Domain
Luke et al [21]: Mortality and
Serious Adverse Events Ortiz et al [22]: Mortality
Stockman et al [7]:
Serious Adverse Events
Study question Low risk of bias Moderate risk of bias Low risk of bias
Search strategy Low risk of bias Moderate risk of bias Moderate risk of bias
Inclusion and exclusion criteria Moderate risk of bias Low risk of bias Low risk of bias
Interventions Moderate risk of bias Moderate risk of bias Low risk of bias
Outcomes Low risk of bias Moderate risk of bias Low risk of bias
Data extraction Moderate risk of bias Moderate risk of bias Moderate risk of bias
Study quality and validity Low risk of bias Low risk of bias Moderate risk of bias
Data synthesis and analysis Low risk of bias Low risk of bias Low risk of bias
Results Low risk of bias Moderate risk of bias Low risk of bias
Discussion Low risk of bias Low risk of bias Moderate risk of bias
Funding or sponsorship Low risk of bias Low risk of bias Low risk of bias
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Spanish Inﬂuenza A(H1N1) Infection
A systematic review and meta-analysis by Luke et al [21] showed
that treatment with convalescent plasma, serum, or blood was as-
sociated with a signiﬁcant absolute reduction of 21% (95% CI,
15%–27%) in the pooled CFR. Statistical heterogeneity was low
(I2 = 29.3%), although interventions were clinically heteroge-
neous. Of the 6 studies included in the meta-analysis, 2 reported
use of convalescent whole blood; however, these studies only con-
tributed 84 patients (25%) in the treatment group. When timing
of treatment was recorded, patients who received early treatment
(<4 days from pneumonia onset) had a CFR of 19% (28 of 148),
compared with 59% (49 of 83) for those treated later [21].
Only 2 studies of convalescent serum reported a comparator
group [38, 47]. Both reported absolute reductions in CFR after
treatment, with a reduction of 19% (95% CI, 11%–48%) in one
and 22% (95% CI, 11%–32%) in the other; the reduction in the
latter reached statistical signiﬁcance (P = .008). The remaining
studies observed a CFR ranging from 0% (0 of 2) to 48% (12
of 25) after treatment (Supplementary Table 3). A signiﬁcant
absolute reduction in the CFR was observed in a case series of
157 cases, 46 of whom received convalescent plasma (absolute
reduction in the CFR, 18%; 95% CI, 8% to 30%; P = .0075) [33].
A further study of patients treated with convalescent plasma re-
ported a CFR of 50% (7 of 14) [41].
The majority of studies on Spanish inﬂuenza A(H1N1) infec-
tion were found to have high risk of bias due to the use of now
archaic research methods and a risk of wartime censorship and
publication bias [21].
Exploratory Post Hoc Meta-analysis
The post hoc meta-analysis evaluated pooled data from 8 com-
parative studies: 2 studies of SARS-CoV infection [32, 46], 2 of
inﬂuenza A(H1N1)pdm09 infection [30, 48], 1 of avian inﬂuenza
A(H5N1) infection [36], and 3 of Spanish inﬂuenza A(H1N1)
infection [33, 38, 47]. There was a statistically signiﬁcance
lower risk of mortality in the group treated with convalescent
plasma or serum (pooled OR, 0.25; 95% CI, .14 to .45;
P < .001; I2 = 0%; Figure 3). Examination of the funnel plot
and ﬁndings of the Egger test showed no evidence of publica-
tion bias. Sensitivity analyses that excluded studies with ≤5
cases demonstrated little variation in the pooled OR or change
in statistical heterogeneity (Figure 4).
Meta-analysis of the crude CFR in treated patients was reject-
ed due to excessive statistical heterogeneity (I2 = 85%). Sensitiv-
ity analysis that excluded studies with ≤5 cases did not account
for this and was similarly abandoned (I2 = 91%).
Hospital Length of Stay
Convalescent plasma treatment was associated with a signiﬁcant
increase in the proportion of SARS-CoV–infected patients dis-
charged within 22 days of admission in 1 center (absolute dif-
ference, 54%; 95% CI, 25%–85%; P = .004) after excluding
patients with comorbidities from the analysis (Table 3) [46].
A further SARS-CoV infection case series [31] reported that
47% of patients (15 of 33) were discharged by day 22, and ini-
tiation of therapy was signiﬁcantly earlier among patients dis-
charged by that time (mean number of days from symptom
onset, 11.67 vs 16.04; P < .001). Both studies were at moderate
to high risk of selection bias and confounding by indication. A
case-comparison study at moderate risk of bias [30] reported no
signiﬁcant difference in length of hospital stay between treat-
ment and control patients with severe pandemic inﬂuenza A
(H1N1) infection who required ECMO (Table 3).
Duration of Critical Care Support
A retrospective observational study [30] reported that conva-
lescent plasma treatment made nonsigniﬁcant reductions to
the length of time spent in the intensive care unit, days of
Figure 2. Summary of outcome level risk of bias assessments in eligible observational studies, using the Newcastle Ottawa tool (excluding prospective
cohort studies; 44 outcomes from 25 studies).
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Table 3. Summary of Narrative Synthesis
No. of Patients,
Viral Etiology
Patients
Evaluated, No.
Mortality
Intervention, 699; Control, 568;
Unknown, 60
Length of Hospital Stay
Intervention, 92; Control, 16
Critical Care Support
Intervention, 92; Control, 16
Antibody Levels
Intervention, 4; Control, 0
Viral Load
Intervention, 7; Control, 0;
Unknown, 44
Adverse Events
Not Reported at
Patient Level
SARS-CoV The absolute reduction in the
risk of mortality varied from
7% (95% CI, −2.39 to 18.68)
to 23% (95% CI, 5.59–42.02)
in 2 studies at medium to
high risk of bias. Subgroup
analyses suggested that
early treatment was
beneficial. Four
noncomparative studies
found that the CFR varied
from 0% (0/1) to 12.5% (10/
80).
The likelihood of discharge
by day 22 was 54%greater
(95% CI, 24.8%–84.6%)
after treatment (77% vs
23%) in 1 study. A
noncomparative study
reported that 47% of
treated patients were
discharged by day 22, both
of which were at moderate
to high risk of bias. Results
suggest that early
treatment is beneficial.
No data were reported in
identified studies.
No comparative data
were reported.
Increased antibody
levels were detected
up to day 5 after
treatment in 1 study of
healthcare workers,
which was at high risk
of bias.
No comparative data were
reported. A decrease in viral
load was reported after
treatment in 1
noncomparative study,
which was at high risk
of bias.
No adverse events
or complications
were reported
after treatment.
Influenza A
(H1N1)
pdm09
A relative reduction in the odds
of mortality of 80% (adjusted
odds ratio, 0.20; 95% CI,
.06–.69) was reported in 1
prospective study, which
was at moderate risk of bias.
Subgroup analyses suggest
that early treatment was
beneficial. One comparative
study showed no significant
benefit. Two
noncomparative studies
found that the CFR varied
from 0% (0/1) to 25% (0/4).
The mean duration of stay
was shorter after
treatment (36.6 d vs 60 d;
P= .23) in 1 study, which
was at moderate risk of
bias.
Reductions in the length of
ICU stay (reduction in
mean duration, 3.34 d),
mechanical ventilation (4
d), and ECMO (10.3 d)
were reported by 1 study,
which was at moderate
risk of bias.
No data were reported in
identified studies.
Significantly lower viral load
after treatment was
observed at days 3, 5, and 7
after ICU admission in
subgroup analysis of 1
prospective study, which
was at moderate to high risk
of bias. One
noncomparative study
found a reduction in viral
load after treatment.
No adverse events
or complications
were reported
after treatment.
Avian influenza
A(H5N1)
Nonsignificant benefits
following intervention were
reported in 1 study with
comparator data. Three case
reports reported no deaths.
No comparative data were
reported. The length of
hospital stay was 94 d in a
case report at high risk of
bias.
No comparative data were
reported. One case
report, which had a high
risk of bias, cited that
treatment allowed
discontinuation of
mechanical ventilation.
Specific antibodies were
detected between day
7 and day 16 after
treatment in a case
report at high risk of
bias.
No comparative data were
reported. Three studies
reported reductions in viral
load after treatment.
No adverse events
or complications
were reported
after treatment.
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Table 3 continued.
No. of Patients,
Viral Etiology
Patients
Evaluated, No.
Mortality
Intervention, 699; Control, 568;
Unknown, 60
Length of Hospital Stay
Intervention, 92; Control, 16
Critical Care Support
Intervention, 92; Control, 16
Antibody Levels
Intervention, 4; Control, 0
Viral Load
Intervention, 7; Control, 0;
Unknown, 44
Adverse Events
Not Reported at
Patient Level
Spanish
influenza A
(H1N1)a
A pooled absolute reduction of
21% (95% CI, 15%–27%)in
the CFR was reported by a
meta-analysis at low risk of
bias. This pooled 6 studies,
including 2 studies using
convalescent blood.
Subgroup analyses
suggested that early
treatment was beneficial.
The absolute reduction in the
risk of mortality ranged from
18.66% (95% CI, 10.62%–
47.95%) to 21.60% (95% CI,
11.2%–31.93%) in 3 studies
at high risk of bias. Ten
noncomparative studies
found that the CFR varied
from 0% (0/2) to 50% (7/14).
No data were reported in
identified studies.
No data were reported in
identified studies.
No data were reported in
identified studies.
No data were reported in
identified studies.
Three studies
reported chills,
increased
temperature,
and sweats after
infusion.
Abbreviations: CFR, case-fatality rate; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; influenza A(H1N1)pdm09, 2009 pandemic influenza A(H1N1); SARS-CoV, severe acute
respiratory syndrome coronavirus.
a All studies reported use of convalescent plasma, except 11 studies, in which convalescent serum was used to treat Spanish influenza A(H1N1) infection, and 1 meta-analysis of 6 studies, 2 of which reported use of
convalescent blood to treat Spanish influenza A(H1N1) infection. Additional data pertaining to individual studies (including comparator data, where presented) are available in the Supplementary Materials.
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mechanical ventilation, or number of days of ECMO for 6 pa-
tients with severe pandemic inﬂuenza A (H1N1)pdm09 infec-
tion (Table 3). Two other case reports of pandemic inﬂuenza
A (H1N1)pdm09 infection [24] and avian inﬂuenza A(H5N1)
infection [27] also suggested that convalescent plasma may
have aided clinical improvement and reduced the duration of
mechanical ventilation.
Viral Antibody Levels
We identiﬁed limited evidence relating to levels of viral antibod-
ies after convalescent plasma treatment; studies did not use a
comparator and were at high risk of bias. Peaks in SARS-CoV
antibody levels occurred 3–5 days following receipt of a single
dose of convalescent plasma in 3 healthcare workers (Table 3)
[8]. However, it is likely that other treatments, such as
Figure 3. Forest plot of pooled odds ratios (ORs) of mortality following treatment with convalescent plasma or convalescent serum (n = 8 studies).
Weights are from random-effects analysis. Abbreviation: CI, conﬁdence interval.
Figure 4. Forest plot of pooled odds ratios (ORs) of mortality following treatment with convalescent plasma or convalescent serum, excluding studies
with <5 patients (n = 5 studies). Weights are from random-effects analysis. Abbreviation: CI, conﬁdence interval.
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intravenous immunoglobulin, ribavirin and steroids, may have
inﬂuenced the relationship between plasma and antibody levels.
A case report of a patient with avian inﬂuenza A(H5N1) infec-
tion also found that virus-speciﬁc antibodies appeared 7–16
days following administration of convalescent plasma [23].
Viral Load
The SARS-CoV load in the respiratory tract decreased at a high-
er rate in patients who received convalescent plasma in a sub-
group analysis of 44 patients with inﬂuenza A(H1N1)pdm09
infection in a prospective cohort study (Table 3); [48] viral
loads were signiﬁcantly lower 3, 5, and 7 days after intensive
care unit admission. However, there was a high risk of selection
bias for this outcome, and concomitant treatments, including
oseltamivir, zanamivir, and corticosteroids, may have con-
founded the results.
Further studies reported that viral load became rapidly unde-
tectable in the blood of 3 patients with SARS-CoV infection [8]
and in respiratory tract specimens from a patient infected with
inﬂuenza A(H1N1)pdm09 [24] after treatment. Similar decreases
in viral loads in serum and respiratory tract specimens were ob-
served in 3 cases of avian inﬂuenza A(H5N1) infection, with virus
becoming undetectable 2–3 days after initiation of convalescent
plasma treatment for 2 cases and 7–16 days after treatment initi-
ation for the third case (Supplementary Table 3) [23, 26, 36].
Severe Adverse Events and Treatment Complications
No studies reported a serious adverse event, and few studies re-
ported information about treatment complications, although
minor complications may be underreported in the literature.
Two observational studies [8, 46] concerned with SARS-CoV in-
fection reported that treatments did not cause harm when ad-
ministered to patients. One study involving inﬂuenza A(H1N1)
pdm09 infection reported that no adverse events were observed
in the treatment group [48].
Three studies from 1918–1920 (involving 101–157 patients
with inﬂuenza) reported minor infusion complications, includ-
ing chills, increased temperature [34, 44], and sweats [33]. A
study of 14 patients did not report chills or any serious compli-
cations. The methods and reporting of these studies reﬂect the
period during which they were conducted, and the studies are
therefore at high risk of bias.
DISCUSSION
Our analyses suggest that convalescent plasma may have a clin-
ically relevant impact in reducing the rate of mortality and viral
load in patients with SARI of viral etiology. Post hoc pooled
meta-analysis across all viral etiologies showed a statistically sig-
niﬁcant 75% reduction in the odds of mortality among those
who were treated with convalescent plasma or serum. We
found no evidence of serious adverse events or complications
due to therapy and limited evidence of a reduction in the use
of critical care resources and the length of hospital stay.
Of interest is the evidence for a survival beneﬁt after early ad-
ministration. A recent multicenter, prospective, double-blind,
randomized control trial compared the use of hyperimmune
immunoglobulin (derived from inﬂuenza A(H1N1)pdm09 con-
valescent plasma) to intravenous immunoglobulin manufac-
tured before the 2009 pandemic [5]. For 22 patients from this
study who received treatment within 5 days of symptom onset
and were excluded per protocol, a multivariate subgroup anal-
ysis demonstrated that hyperimmune immunoglobulin had a
protective effect (OR, 0.14; 95% CI, .02–.92) [5]. Evidence
from studies of SARS-CoV infection [31] and Spanish inﬂuenza
A(H1N1) infection [21] showed a survival beneﬁt following
convalescent plasma treatment within 14 days and 4 days of
symptom onset, respectively. These ﬁndings suggest that early
initiation of treatment may be of critical importance to reducing
mortality in patients with SARI of viral etiology.
Limitations
A lack of high-quality studies and a paucity in the volume of
relevant literature limited our analyses. Observational studies
were predominately case reports or series, had no control
groups, and had a moderate to high risk of bias. Findings
were commonly at high risk of confounding by indication. Al-
though selection or reporting bias may favor the intervention,
recruiting patients who are clinically deteriorating or moribund
would bias the result in the opposite direction. Adequate meth-
odological or statistical measures were infrequently used to con-
trol bias and confounding, and we identiﬁed numerous sources
of clinical and methodological heterogeneity. We cannot be as-
sured that all Spanish inﬂuenza A(H1N1) infection studies were
included since our protocol did not include hand searching of
literature from 1918–1920. Although our post hoc meta-
analyses were undertaken to help inform clinical decision mak-
ing, the theoretical rationale for pooling mortality data from dif-
ferent viral etiologies remains to be fully established. The results
obtained must be considered experimental and interpreted with
an appropriate level of caution.
Implications for Practice
We did not identify any reports of convalescent plasma use for
patients with MERS-CoV infection. The evidence for a reduction
in mortality associated with convalescent plasma is strongest for
SARS and inﬂuenza A(H1N1)pdm09 infection. Although it is
clinically rational to consider novel therapies for critically ill pa-
tients, there is evidence that maximum beneﬁt from convalescent
plasma might be realized through early initiation of therapy.
However, many treatment protocols currently mention convales-
cent plasma as a treatment of last resort. If this treatment is con-
sidered for MERS-CoV–infected patients with SARI, it should
ideally only be administered in acute centers able to manage
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potential treatment-related complications, such as transfusion-
related acute lung injury. We consider this a precautionary ap-
proach because of the limited clinical experience of administering
convalescent plasma to this patient group.
Further Research Needs
Improved knowledge regarding the mode of action of convales-
cent plasma and the virologic and immunologic kinetics of novel
respiratory infections that cause SARI (such as MERS-CoV) are
needed. This would help clarify the potential beneﬁts and harms
of treatment, identify optimal dosage, and ascertain whether re-
peated treatments are relevant factors for clinical practice. Ran-
domized controlled trials or observational studies that adopt a
standardized minimum data set are needed to better evaluate
convalescent plasma as a therapeutic option for MERS-CoV in-
fection before it can be fully recommended or before reﬁnements
can be made over its current use, other than our current recom-
mendation for early use. The WHO and the International Severe
Acute Respiratory and Emerging Infection Consortium are cur-
rently developing a clinical trial protocol to investigate the effec-
tiveness of passive immunotherapy for patients with SARI.
Conclusion
Available evidence suggests that convalescent plasma is likely to
reduce mortality during SARIs of viral etiology, with larger
treatment effects if it commenced early after symptom onset.
However, this is based on predominately low-quality, uncon-
trolled studies. Our review supports the use of convalescent
plasma in critically ill MERS-CoV–infected patients as part of
a well-designed clinical trial or other formal evaluation.
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